Families caring for loved ones with advanced dementia and severe agitation now have a new piece of clinical evidence to weigh. A Phase II randomized, double-blind, placebo-controlled trial called LiBBY, which enrolled roughly 120 hospice-eligible patients with dementia-related agitation, reported that a proprietary oral formulation containing both cannabidiol and tetrahydrocannabinol reduced agitation scores on the Cohen-Mansfield Agitation Inventory (CMAI) at two weeks. The results, announced by MediPharm Labs on July 14, 2026, add to a small but growing body of controlled research on cannabinoids for one of dementia care’s most distressing symptoms.
Why hospice-level agitation in dementia lacks good options
Agitation in advanced dementia is not a minor behavioral nuisance. It includes hitting, screaming, pacing, and resisting care, and it drives burnout among family caregivers and staff in hospice and long-term care settings alike. Existing pharmacological treatments, chiefly antipsychotics and sedatives, carry serious risks for older adults, including falls, stroke, and increased mortality. That gap between clinical need and safe medication helps explain why a mid-stage cannabis trial in this population has attracted attention beyond the usual research audience.
The LiBBY trial specifically targeted patients who were hospice-eligible and experiencing clinically significant agitation alongside a dementia diagnosis. According to the registered protocol, the study randomized approximately 120 participants and measured change on the CMAI, a validated agitation scale, as its primary outcome at the two-week mark. That short time horizon reflects the realities of end-of-life care, where speed of symptom relief matters more than long-term disease modification.
MediPharm Labs, the Canadian company that developed and supplied the oral cannabinoid formulation used in the trial, issued a press release claiming the results showed a significant reduction in agitation and referenced durability of the effect beyond the initial endpoint. Because the full peer-reviewed manuscript has not yet been published, the specific effect sizes, confidence intervals, and safety data remain available only through the company’s topline summary. That distinction matters: corporate announcements routinely highlight favorable endpoints and may not fully detail adverse events, subgroup differences, or negative secondary outcomes.
Prior cannabinoid trials show mixed signals on agitation
The LiBBY results do not exist in a vacuum. Several earlier randomized controlled trials tested different cannabinoid compounds for dementia-related behavioral symptoms, and the collective picture is uneven.
A peer-reviewed trial of dronabinol, a synthetic form of THC, enrolled 75 patients with Alzheimer’s disease across multiple sites between 2017 and 2024. That study found a signal of reduced agitation on at least one co-primary outcome, but sedation emerged as a potential safety concern, according to the published data. The authors emphasized that while some participants experienced calmer behavior, others developed drowsiness or worsened confusion, underscoring the narrow therapeutic window for psychoactive cannabinoids in frail older adults.
An earlier trial of nabilone, a synthetic THC analog, in patients with Alzheimer’s-related agitation also used the CMAI and reported improvements in agitation scores along with what investigators described as a tolerable safety profile. The LiBBY investigators directly cited that nabilone study as prior evidence supporting their choice of a THC-containing regimen. In that research, clinicians noted reductions in verbal and physical aggression but also observed increased somnolence in some participants, again pointing to a trade-off between calming agitation and preserving alertness.
A separate placebo-controlled trial examined cannabidiol-rich oil for behavioral disturbances in dementia patients, aiming to clarify whether CBD-dominant regimens might offer calming effects without the psychoactive risks associated with THC. While some measures of agitation and neuropsychiatric symptoms improved, the effect sizes were modest, and not all endpoints reached statistical significance. Together, these trials suggest that both THC and CBD can influence agitation, but their relative contributions and optimal ratios remain unsettled.
On the other side of the ledger, a randomized controlled trial of THC alone for neuropsychiatric symptoms in dementia found no statistically significant differences on agitation measures compared with placebo in a small sample. The authors acknowledged limited statistical power and variability in baseline behaviors, but the null result serves as a reminder that positive findings from one cannabinoid formulation do not automatically extend to others. Active compounds, doses, CBD-to-THC ratios, routes of administration, and patient characteristics vary enough across these studies that direct comparisons require caution.
Open questions about LiBBY’s real-world impact
The most pressing gap is the absence of a full peer-reviewed publication for the LiBBY trial. Until independent reviewers and the broader research community can examine the complete dataset, including dropout rates, adverse event profiles, and whether the CMAI improvements reached thresholds that translate into meaningful day-to-day relief for patients and caregivers, the corporate announcement alone cannot anchor clinical decisions. The trial’s two-week primary endpoint, while practical for a hospice population, also leaves open whether the benefit persists or fades over longer periods of use.
Regulatory status adds another layer of uncertainty. The formulation used in LiBBY is a proprietary product from MediPharm Labs, and a Phase II trial by itself does not guarantee that regulators will ultimately authorize it as a licensed medicine for dementia-related agitation. Agencies typically require at least one larger Phase III trial demonstrating consistent efficacy and an acceptable safety margin before approving a new indication. Even if subsequent studies confirm benefit, prescribers will still have to weigh the drug’s psychoactive properties, potential for drug–drug interactions, and the vulnerability of hospice patients to side effects such as falls, delirium, and aspiration.
Real-world implementation would raise practical questions as well. Hospice and long-term care teams would need clear guidance on dosing, titration, and monitoring, especially in patients already taking antipsychotics, benzodiazepines, or opioids. Families might welcome a treatment framed as more “natural” than traditional psychotropics, but expectations would need to be tempered by candid discussions about limited evidence, possible sedation, and the fact that cannabinoids are unlikely to resolve all behavioral symptoms.
Equity and access issues are also likely to emerge. If the LiBBY formulation advances to market as a branded product, cost could restrict availability for patients in publicly funded hospice programs or in regions with limited insurance coverage for novel neuropsychiatric drugs. At the same time, the publicity surrounding LiBBY may encourage off-label use of existing cannabis products that have not been rigorously tested in this population, potentially exposing frail patients to unstandardized doses and variable purity.
What caregivers and clinicians can do now
For now, the LiBBY trial should be viewed as an encouraging but preliminary signal rather than a practice-changing breakthrough. Families facing severe agitation in advanced dementia still need to rely on a mix of nonpharmacologic strategies-such as environmental modifications, pain assessment, and structured routines-alongside cautious use of existing medications when safety is at risk. Clinicians considering cannabinoid options should discuss the current evidence base, including the mixed results from prior trials and the lack of long-term data in hospice-level patients.
As full LiBBY results move through peer review and additional studies emerge, the field may gain a clearer picture of which patients are most likely to benefit from cannabinoid-based treatments, at what doses, and with what monitoring. Until then, careful attention to symptom triggers, caregiver support, and individualized care plans remains the foundation of managing agitation at the end of life, with cannabinoids occupying a promising but still provisional place in the therapeutic toolbox.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
